Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Nesolicaftor (PTI-428) in CF Patients on Kalydeco
NCT03258424Phase 1Completed
- Sponsor
- Proteostasis Therapeutics
- Start
- Jul 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) comparing PTI-428 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jul 2017; status: completed.
02
Drugs
nesolicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03258424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258424.